KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Cash from Investing Activities: 2009-2025

Historic Cash from Investing Activities for Neogenomics (NEO) over the last 17 years, with Sep 2025 value amounting to -$277,000.

  • Neogenomics' Cash from Investing Activities rose 92.12% to -$277,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.5 million, marking a year-over-year decrease of 132.37%. This contributed to the annual value of $12.9 million for FY2024, which is 83.24% down from last year.
  • Neogenomics' Cash from Investing Activities amounted to -$277,000 in Q3 2025, which was up 97.03% from -$9.3 million recorded in Q2 2025.
  • Neogenomics' Cash from Investing Activities' 5-year high stood at $23.7 million during Q1 2023, with a 5-year trough of -$453.4 million in Q2 2021.
  • Over the past 3 years, Neogenomics' median Cash from Investing Activities value was $7.3 million (recorded in 2024), while the average stood at $7.6 million.
  • In the last 5 years, Neogenomics' Cash from Investing Activities plummeted by 2,396.34% in 2021 and then surged by 1,717.59% in 2023.
  • Over the past 5 years, Neogenomics' Cash from Investing Activities (Quarterly) stood at -$9.6 million in 2021, then skyrocketed by 88.91% to -$1.1 million in 2022, then surged by 1,717.59% to $17.2 million in 2023, then plummeted by 131.79% to -$5.5 million in 2024, then skyrocketed by 92.12% to -$277,000 in 2025.
  • Its Cash from Investing Activities stands at -$277,000 for Q3 2025, versus -$9.3 million for Q2 2025 and $3.6 million for Q1 2025.